Adaptive trials in the neoadjuvant setting: A model to safely tailor care while accelerating drug development

Journal of Clinical Oncology

Volumn 30, Issue 36, 2012, Pages 4584-4586

  Yee, Douglas ^a   Haddad, Tufia ^b   Albain, Kathy ^c   Barker, Anna ^d   Benz, Christopher ^e   Boughey, Judy ^b   Buxton, Meredith ^f   Chien, Amy Jo ^f   DeMichele, Angela ^g   Dilts, David ^h   Elias, Anthony ⁱ   Haluska, Paul ^b   Hogarth, Michael ^j   Hu, Alan ^k   Hytlon, Nola ^f   Kaplan, Henry G ^l   Kelloff, Gary G ^m   Khan, Qamar ⁿ   Lang, Julie ^o   Leyland Jones, Brian ^p   Liu, Minetta ^q   Nanda, Rita ^r   Northfelt, Donald ^s   Olopade, Olufunmilayo I ^r   Park, John ^f   Parker, Barbara ^t   Parkinson, David ^u   Pearson White, Sonia ^v   Perlmutter, Jane ^w   Pusztai, Lajos ^x   Symmans, Fraser ^y   Rugo, Hope ^f   Tripathy, Debu ^y   Wallace, Anne ^z   Wholley, David ^v   Van't Veer, Laura ^f   Berry, Donald A ^x   Esserman, Laura ^g   more..

^a UNIVERSITY OF MINNESOTA   (United States)

^b MAYO CLINIC CANCER CENTER   (United States)

^c LOYOLA UNIVERSITY HEALTH SYSTEM   (United States)

^d ARIZONA STATE UNIVERSITY   (United States)

^e BUCK INSTITUTE FOR RESEARCH ON AGING   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g UNIVERSITY OF PENNSYLVANIA   (United States)

^h OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

ⁱ UNIVERSITY OF COLORADO   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k Quantum Leap Healthcare Collaborative   (United States)

^l SWEDISH MEDICAL CENTER   (United States)

^m NATIONAL CANCER INSTITUTE   (United States)

ⁿ UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^o UNIVERSITY OF ARIZONA   (United States)

^p SANFORD HEALTH   (United States)

^q GEORGETOWN UNIVERSITY   (United States)

^r UNIVERSITY OF CHICAGO   (United States)

^s MAYO CLINIC   (United States)

^t UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^u Nodality   (United States)

^v NATIONAL INSTITUTES OF HEALTH   (United States)

^w Gemini Group   (United States)

^x UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^y UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^z UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL; TAMOXIFEN;

BREAST CANCER; DRUG COST; FEMALE; HUMAN; LETTER; PATIENT SAFETY; PRIORITY JOURNAL;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARCINOMA IN SITU; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; MASTECTOMY; NEOADJUVANT THERAPY;

EID: 84871764835     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.44.1022     Document Type: Letter

References (8)

1. Schott AF, Hayes DF: Defining the benefits of neoadjuvant chemotherapy for breast cancer. J Clin Oncol 30:1747-1749, 2012
2. van de Vijver MJ, He YD, van't Veer LJ, et al: A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999-2009, 2002
3. Symmans WF, Peintinger F, Hatzis C, et al: Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy. J Clin Oncol 25:4414-4422, 2007
4. Barker AD, Sigman CC, Kelloff GJ, et al: I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther 86:97-100, 2009
5. Esserman LJ, Woodcock J: Accelerating identification and regulatory approval of investigational cancer drugs. JAMA 306:2608-2609, 2011
6. Osborne CK, Kitten L, Arteaga CL: Antagonism of chemotherapy-induced cytotoxicity for human breast cancer cells by antiestrogens. J Clin Oncol 7:710-717, 1989
7. Albain KS, Barlow WE, Ravdin PM, et al: Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: A phase 3, open-label, randomised controlled trial. Lancet 374:2055-2063, 2009
8. Meropol NJ, Kris MG, Winer EP: The American Society of Clinical Oncology's blueprint for transforming clinical and translational cancer research. J Clin Oncol 30:690-691, 2012